** Shares of Lucid Diagnostics LUCD.O down ~25% to $1.24 in extended trading on equity raise plans
** New York-based commercial-stage subsidiary of PAVmed Inc PAVM.O announces stock offering without disclosing deal size
** With ~90.75 mln shares outstanding, co has about $150 mln market cap
** Stock on Weds finished up 1.9% at $1.65. Shares ended 2024 at 82 cents
** Canaccord Genuity sole bookrunner for proposed offering
** Lucid says it's focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.